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Goals
• Brief Review of IMM
• Outline the validation process
• Illustrate and compare results
• Discuss implications to decision making
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Integrated Medical Model (IMM)
• Stochastic simulation model used to predict in-flight medical events, 
the resources required to treat, and impacts to the spaceflight mission.
• Human Research Program supported development since before FY08.
• v4.1 transitioned to use by Crew Health and Safety in 2017.
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Purpose of the Comparison – Validation
Compare IMM output to 
observed medical 
events from a selection 
of Shuttle 
Transportation System 
(STS) and International 
Space Station (ISS) 
missions.
National Aeronautics and Space Administration
www.nasa.gov
What Data is Used for Comparison?
• Real World System (RWS): 31 ISS and 21 STS missions 
not previously incorporated into the primary IMM data 
repository*
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*Integrated Medical Database, iMED
STS 115 through STS 135 and 
STS 107
ISS Expedition (Exp) 14 through 
39/40 and ISS Exp 9
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IMM Simulations of the RWS Missions
Equivalent simulations performed for each RWS mission 
profile using IMM v 4.0
• Length of mission
• Mission schedule (EVA)
• Crew complement (sex, limited medical history)
• ISS simulation assumed resupply of medical supplies
• 100 Medical condition set
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Observed and Predicted Outcomes
• Total medical events (TME)
• Medical consumable utilization 
• LOCL and EVAC*
* RWS had zero LOCL and EVAC events
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(Cumulative) Total Medical Events
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Predicted (P)
Observed (O) 
IMM medical conditions list only (mc)
STS ISS
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Per Condition Comparison
• 20% of the STS and 15% of the ISS medical events 
within expected uncertainty.
• 14% for STS and 24% for ISS medical events outside 
of the expected uncertainty.
• The remainder of the events had an indeterminate 
comparison. 
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Out of Range ISS Conditions
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Over predicted the number of events for all but 6 conditions.
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Out of Range STS Conditions
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Under predicted the number of events for all but two conditions.
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ISS – Medical Consumables
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Observed 
Rank
Observed (from 
TME_O_mc)
Predicted 
Rank
Predicted (from TME_P) Quality of Match 
1 Non-opioid Analgesics 1 Non-opioid Analgesics Excellent
2 Hypnotics 2 Hypnotics Excellent
3 Antiemetics 6 Antiemetics Fair
4 Antihistamines 4 Antihistamines Excellent
5 Steroids 13 Steroids Poor
6 Decongestants 7 Decongestants Excellent
7 Antibiotics 3 Antibiotics Fair
8 Ophthalmic Lubricants 5 Ophthalmic Lubricants Fair
9 Antifungals 9 Antifungals Excellent
10 Antacids 12 Antacids Excellent
11 Antidiarrheals 8 Antidiarrheals Fair
12 Laxatives 10 Laxatives Excellent
13 Antivirals 14 Antivirals Excellent
14 Opioid Analgesics 11 Opioid Analgesics Fair
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STS - Medical Consumables
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Observed 
Rank
Observed (from 
TME_O_mc)
Predicted 
Rank
Predicted (from TME_P) Quality of Match 
1 Hypnotic 4 Hypnotic Fair
2 Antiemetic 2 Antiemetic Excellent
3
Non-opioid 
Analgesic/NSAID 1
Non-opioid Analgesic/NSAID
Excellent
4 Decongestant 3 Decongestant Excellent
5 Laxative 6 Laxative Excellent
6 Antibiotic 5 Antibiotic Excellent
7 Steroid 8 Steroid Excellent
8 Ophthalmic Lubricants 9 Ophthalmic Lubricants Excellent
9 Antidiarrheal 10 Antidiarrheal Excellent
10 Antacid 13 Antacid Fair
11 Antihistamine 7 Antihistamine Fair
12 Antifungal 11 Antifungal Excellent
13 Opioid Analgesic 12 Opioid Analgesic Excellent
14 Antiviral 14 Antiviral Excellent
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LOCL and EVAC Comparison
• Predicted counts are estimated using the median of the simulated 
distribution.
• A confidence limit of (0, 0) indicates that more than 90% of the 
generated LOCL counts was 0 as these confidence limits are estimated 
by the 5th and 95th percentiles of the simulation distribution.
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STS
Predicted 
Number
90% Confidence 
Interval
EVAC RWS = 0 0 0, 1
LOCL RWS = 0 0 0, 0
ISS
Predicted 
Number
90% Confidence 
Interval
EVAC RWS = 0 0 0, 1
LOCL RWS = 0 0 0, 0
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Potential Implications on Decision Making
• Variation exists in IMM predictive power for STS and ISS 
missions
• Decision should account for information limits
– Longer mission profile - IMM tends to over predict incidences
– Shorter mission profiles  - IMM tends to under predict incidence. 
• Difference in predictions 
– Different ISS and STS reporting conditions.
– Combining all “mission type” data 
– Constant occurrence rate or fixed proportion. 
National Aeronautics and Space Administration
www.nasa.gov
Future Work (Some Already Done!)
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• Incorporation RWS data into the iMED (Completed)
• Transition to CHS (Completed)
• CHS acceptance testing (On going)
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